Acquired Company

TapImmune Inc. completed its merger with privately-held Marker Therapeutics, Inc. on 10/17/2018, and the combined company began trading under the MRKR ticker after TapImmune changed its name to Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. Show more

2450 Holcombe Blvd, Houston, TX, 77021, United States

https://markertherapeutics.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

19.02M

52 Wk Range

$0.81 - $4.07

Previous Close

$1.47

Open

$1.45

Volume

264,419

Day Range

$1.45 - $1.64

Enterprise Value

1.312M

Cash

17.59M

Avg Qtr Burn

-2.736M

Insider Ownership

5.49%

Institutional Own.

24.26%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MT-601 (Neldaleucel) Details Non-Hodgkin Lymphoma (NHL)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MT-401-OTS Details Acute myeloid leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MT-601 (Neldaleucel) + chemotherapy Details Pancreatic cancer	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MT-401 Details Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.